Effects of Tocilizumab in COVID-19 patients: a cohort study

BACKGROUND: Due to the lack of proven therapies, we evaluated the effects of early administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab may help to mitigate the hyperinflammatory response associated with progressive respiratory failure from SARS-CoV-2. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Vu, Christine A., DeRonde, Kailynn J., Vega, Ana D., Maxam, Meshell, Holt, Gregory, Natori, Yoichiro, Zamora, Jose Gonzales, Salazar, Veronica, Boatwright, Renata, Morris, Stephen R., de Lima Corvino, Daniela, Betances, Anmary Fernandez, Colucci, Leah, Keegan, James, Lopez, Andy, Rezk, Andrew Hany, Rodriguez, Yvette, Moraru, Gabriela M., Doblecki, Susanne, De La Zerda, David J., Abbo, Lilian M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755065/
https://www.ncbi.nlm.nih.gov/pubmed/33353546
http://dx.doi.org/10.1186/s12879-020-05701-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755065/
https://www.ncbi.nlm.nih.gov/pubmed/33353546
http://dx.doi.org/10.1186/s12879-020-05701-4

Ejemplares similares